Two of the most-researched compounds in metabolic science, directly compared. Semaglutide (GLP-1 only) versus tirzepatide (GLP-1 + GIP dual agonist). Here's what the data actually shows and what it means for research protocol design.
| Parameter | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Average weight loss (trials) | ~14–17% | ~20–22% |
| Head-to-head result | — | Superior (SURPASS-6) |
| Half-life | ~7 days | ~5 days |
| Dosing frequency | Once weekly | Once weekly |
| Years of real-world data | Since 2017 (diabetes) | Since 2022 |
| CV outcome data | SUSTAIN-6, SELECT confirmed | Ongoing (SURPASS-CVOT) |
| GI side effect profile | Similar | Similar |
The key difference is the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is also released after eating and acts on receptors in the pancreas, brain, and adipose tissue. For years, researchers thought GIP receptor activation would reduce the effectiveness of GLP-1 drugs — animal data suggested GIP antagonism could improve weight loss.
Tirzepatide proved that wrong at scale. Adding GIP agonism to GLP-1 agonism appears to have additive or synergistic effects. The current hypothesis involves GIP reducing GI side effects from GLP-1 stimulation while independently contributing to adipose tissue lipolysis and central satiety signaling.
The direct comparison data comes from SURPASS-6 (2023), which compared semaglutide 1mg versus tirzepatide 5mg, 10mg, and 15mg in subjects with type 2 diabetes over 40 weeks.
| Treatment | Mean Weight Loss | HbA1c Reduction |
|---|---|---|
| Semaglutide 1mg | -5.8kg | -1.44% |
| Tirzepatide 5mg | -7.6kg | -1.77% |
| Tirzepatide 10mg | -9.3kg | -1.98% |
| Tirzepatide 15mg | -11.2kg | -2.11% |
Note this used semaglutide 1mg, not the 2.4mg dose used in weight management research. A direct head-to-head at max doses hasn't been conducted — but the SURMOUNT (tirzepatide) vs STEP (semaglutide) programs show ~22% vs ~15% weight loss respectively at comparable populations.
Both compounds share a broadly similar GI side effect profile — nausea, vomiting, diarrhea, constipation. Both require slow titration. Tirzepatide may have a slight edge in tolerability relative to efficacy (more weight loss, similar GI rates), but this hasn't been conclusively established in direct comparison.
One important difference: tirzepatide appears to have a smaller lean mass loss signal in early data, though this needs more long-term study. Both compounds show the same thyroid and pancreatitis precautions.
Choose semaglutide if: you're prioritizing the longest safety data track record, cardiovascular outcome evidence (SELECT trial), or using established STEP trial protocols as your reference.
Choose tirzepatide if: maximum weight loss is the primary endpoint, you want the most current GLP compound before retatrutide, or you're specifically studying dual receptor agonism.
For 3-way comparison including retatrutide, see the full 3-compound comparison.
COA-verified supply for both semaglutide and tirzepatide from our vetted vendors.